Julie Jordan, M.D.

Chief Medical Officer

“I started my career in medicine because I have always wanted to help patients. I was drawn to Homology for the opportunity to develop and deliver potentially life-changing, one-time treatments to patients whose medical needs are not being met with current therapies.”

Dr. Julie Jordan serves as the Chief Medical Officer of Homology Medicines and previously served as Senior Vice President, Head of Clinical Development & Operations. Dr. Jordan has expertise in designing and executing global clinical trials across multiple development areas. Prior to Homology, Dr. Jordan served as Senior Director of Global Clinical Development at Cerevel Therapeutics where she was responsible for clinical and scientific development activities, including global trials for schizophrenia, focal epilepsy and anxiety disorder. Previously, she was Executive Director of global clinical development at Avanir Pharmaceuticals, Inc., responsible for late-stage clinical programs for neuropsychiatry indications. Dr. Jordan held positions of increasing research and development and clinical responsibility at Teva Pharmaceutical Industries, LLC, including serving as clinical development lead for the company’s neuropsychiatry and HIV therapeutic areas. Prior to Teva, she served as Medical Director at Medpace, Inc., where she provided medical expertise and designed and conducted clinical trials across diabetes, cardiovascular disease, women’s health, and gastroenterology. Prior to joining industry, Dr. Jordan was a Clinical Instructor of Medicine at Harvard Medical School, treating patients at Massachusetts General Hospital (MGH). Dr. Jordan holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in internal medicine at MGH, Harvard Medical School.